臨床泌尿器科78巻9号

2024年08月発行

特集 ゲノムアレルギーからの脱却―泌尿器科医がぜひ知っておきたいゲノムの知識

〈がんゲノム検査とエキスパートパネル〉

泌尿器がんにおけるリキッドバイオプシーの有用性と限界

著者： 住吉崇幸¹ 小林恭¹

所属機関： ¹京都大学大学院医学研究科 泌尿器科学講座

ページ範囲：P.666 - P.671

文献概要

▶ポイント

・各ゲノム異常の検出感度は腫瘍細胞由来の血中循環腫瘍DNA（ctDNA）の割合（ctDNA fraction）に依存する．

・薬剤治療歴，転移部位や量，血液検査結果などを参考に，症例ごとにctDNAが十分に含まれているかを検査前に推測しなければならない．

・解析結果のなかには，病態に大きく影響しないサブクローナルな変異，生殖細胞系列変異，腫瘍由来ではない変異が含まれているかもしれないことに注意する必要がある．

参考文献

1） Cancer Genome Atlas Research Network : The Molecular Taxonomy of Primary Prostate Cancer. Cell 163 : 1011-1025, 2015

2） Robertson AG, et al : Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 174 : 1033, 2018

3） Cancer Genome Atlas Research Network : Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499 : 43-49, 2013

4） Wyatt AW, et al : Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst 109 : djx118, 2017

5） Annala M, et al : Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discov 8 : 444-457, 2018

6） Vandekerkhove G, et al : Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun 12 : 184, 2021

7） Fonseca NM, et al : Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun 15 : 1828, 2024

8） Zill OA, et al : The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res 24 : 3528-3538, 2018

9） Warner E, et al : BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clin Cancer Res 27 : 1650-1662, 2021

10） Mizuno K, et al : Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer. Clin Cancer Res 27 : 6164-6173, 2021

11） Kimura H, et al : Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer. Br J Cancer 127 : 1680-1690, 2022

12） de Bono J, et al : Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 382 : 2091-2102, 2020

13） Chi KN, et al : Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clin Cancer Res 29 : 81-91, 2023

14） Abida W, et al : Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol 5 : 471-478, 2019

15） Ritch E, et al : Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. Clin Cancer Res 26 : 1114-1125, 2020

16） Christensen E, et al : Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol 37 : 1547-1557, 2019

17） Powles T, et al : ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595 : 432-437, 2021

18） Tolmeijer SH, et al : Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer. Eur Urol Oncol 7 : 282-291, 2024

19） Loriot Y, et al : Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 389 : 1961-1971, 2023

20） Sumiyoshi T, et al : Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma. Cancer Sci 112 : 3363-3374, 2021

21） Bacon JVW, et al : Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clin. Genitourin. Cancer 18 : 322-331, 2020

22） Herberts C, et al : Technical and biological constraints on ctDNA-based genotyping. Trends Cancer 7 : 995-1009, 2021

23） Vandekerkhove G, et al : Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. JCO Precis Oncol 8 : e2300654, 2024